Sarepta Therapeutics Shares Decline Amid Class Action Lawsuit

Sarepta Therapeutics shares are trading lower after the company faced a class action lawsuit related to allegations of false statements and safety risks of its gene therapy, ELEVIDYS, which has led to patient deaths. RBC Capital cut its price target for Sarepta to $23, maintaining a Sector Perform rating, citing demand pressures and regulatory uncertainties.